A new drug approval for the vanguard of RNA-targeted small molecules
Dark Matter Blog
AUGUST 27, 2020
A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. Dramatic discoveries of small molecules targeting SMN2 Prior to those outstanding therapeutic achievements, in 2015, a group from Novartis published an important paper in Nature Chemical Biology.
Let's personalize your content